Funded Biotechnology Startups in Boston
Boston biotechnology has seen consistent deal flow across the 50 most recent rounds in this dataset, which span April 2023 through November 2025.
Boston biotechnology has seen consistent deal flow across the 50 most recent rounds in this dataset, which span April 2023 through November 2025. The largest disclosed raise is Seaport Therapeutics' $225M Series B from October 2024, followed by Third Arc Bio's $165M Series A (July 2024), Scorpion Therapeutics' $150M Series C (July 2024), and Compass Therapeutics' $120M close in August 2025 — four nine-figure rounds within roughly 13 months.
Series A and Series B rounds each account for approximately nine companies in this set, while "Series Unknown" is the most frequent label, covering roughly 20 companies where stage was not publicly specified. Alys Pharmaceuticals stands out for closing a $100M Seed round in February 2024. At the other end, Eascra Biotech reported a $100K raise in May 2025, illustrating that the dataset captures companies at every point on the maturity curve — from early experiments to late-stage programs like Dewpoint Therapeutics' Series D and Beta Bionics' Series E.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these 50 Boston biotech companies?
Seaport Therapeutics leads with a $225M Series B closed in October 2024, followed by Third Arc Bio at $165M (Series A, July 2024), Scorpion Therapeutics at $150M (Series C, July 2024), Compass Therapeutics at $120M (August 2025), and Axonis Therapeutics at $115M (Series A, October 2024). All five closes occurred within a 13-month window between July 2024 and August 2025.
Which round stages appear most often in this dataset?
"Series Unknown" is the most common label, covering roughly 20 of the 50 companies — a frequent pattern when institutional rounds are disclosed without an explicit stage. Series A and Series B each account for approximately nine companies, making them the two most prevalent labeled stages. Seed rounds (Dash Bio, Orbit Technologies, Propedix, Alys Pharmaceuticals) and Series C rounds (Elektrofi, Scorpion Therapeutics, SmartLabs, Elucid) each represent four companies.
Are there any unusually large early-stage raises in this set?
Alys Pharmaceuticals closed a $100M Seed round in February 2024, which is well above typical seed-stage sizing. Third Arc Bio's $165M Series A (July 2024) and Axonis Therapeutics' $115M Series A (October 2024) are also notable for their scale relative to stage, both exceeding many later-stage closes in the same dataset.
How does deal volume break down by year across these 50 rounds?
The 50 rounds span April 2023 through November 2025. Approximately 19 rounds fall in 2024, 18 in 2023, and 13 in 2025 — though the 2025 count only covers through November and likely undercounts the full year. Annual volume appears relatively stable across the visible window.
What is the smallest raise in the dataset and what does it indicate about the Boston biotech market?
Eascra Biotech reported the smallest disclosed amount at $100K (May 2025), with Apriori Bio ($1M) and Asymmetrex ($2M) also below $5M. Their presence alongside $100M+ closes confirms the dataset captures the full company maturity spectrum, from very early seed-stage experiments to established late-stage therapeutics programs.
Which therapeutic focus areas are visible from company names and descriptions in this group?
Oncology and targeted therapies appear frequently — Scorpion Therapeutics, Elion Therapeutics, Atalanta Therapeutics, and Ikena Oncology all signal that focus. Neurology is represented by PathMaker Neurosystems, Medrhythms, and APRINOIA Therapeutics. Diagnostics names include Day Zero Diagnostics, Leuko, and Elucid, while Dewpoint Therapeutics (Series D) and Ampersand Biomedicines (Series B, $65M) suggest platform-level biology plays.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.